RxDoctor Payments Data

Frederick Balch, DO

Internal Medicine · Saint Louis, MONPI 1154735439

Payments from drug & device makers

$819in general payments, 2019–2025

Across 44 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • Lilly USA, LLC$107
  • Amgen$106
  • GSK$96
  • Pfizer$87
  • AstraZeneca$60
  • plus $252 from 9 others

What the payments were for

  • Food & beverage$819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$819 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$112,985
Medicare patients
329
Services billed
992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$169,791
OzempicSemaglutide108$134,807
MounjaroTirzepatide70$82,367
JardianceEmpagliflozin33$40,445
RybelsusSemaglutide32$37,917
FarxigaDapagliflozin Propanediol37$27,641
JanuviaSitagliptin Phosphate24$26,612
XareltoRivaroxaban26$25,046
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,760
MyrbetriqMirabegron36$16,679
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$15,385
OxycontinOxycodone Hcl25$14,807
MovantikNaloxegol Oxalate20$12,001
ArexvyRsvpref3 Antigen/As01e/Pf43$11,113
SymbicortBudesonide/Formoterol Fumarate38$11,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$87$173,088190 claims
Novo NordiskOzempic, Rybelsus$111$172,725140 claims
Lilly USA, LLCMounjaro$107$82,36770 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$60$47,64289 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta$96$34,64781 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →